Lipocine Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.
The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.
“PCN 1111 is in a very early stage of development. We currently have preliminary data demonstrating absorption of LPCN 1111 in dogs and in postmenopausal females. To our knowledge, this novel ester prodrug has never been administered orally in hypogonadal males and its safety has never been assessed in animal studies.” (Page 16) Read the following document
Lipocine, Inc. engages in the research and development of treatment for use in men’s and women’s health through proprietary drug delivery technologies. It focuses on oral testosterone replacement therapy and preterm birth prevention. The company was founded on July 24, 2013 and is headquartered in Salt Lake City, UT. [Source: MarketWatch]
Company Website: http://www.lipocine.com